What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- How it’s given
- “Sutacimig is a subcutaneously administered, bispecific antibody being developed as a prophylactic treatment option for congenital bleeding disorders.”In the company’s words, NCT07347249 on ClinicalTrials.gov
- Tested for
- Thrombasthenia, Congenital Factor VII Deficiency
- Main trialPhase 3
- “Glanzmann thrombasthenia (GT) is a serious inherited bleeding disorder. In GT, platelets, the blood cells that normally stick together at the site of an injury to stop bleeding, are unable to properly do so. As a result, bleeding does not stop as it should. Bleeding in GT often starts without warning, can happen frequently, and can be severe. It most commonly affects the nose, mouth and gums, gastrointestinal tract, and skin, and many women and girls with GT experience heavy menstrual bleeding. Over time, bleeding can lead to iron deficiency and anemia. Some bleeding episodes require…”In the company’s words, NCT07935356 on ClinicalTrials.gov
Other drugs for Thrombasthenia
- HMB-001Hemab ApS · Phase 1/2
Coming up2
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07935356
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2029 | A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia | |
| Phase 2Recruiting | Nov 2027 | A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026